TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genscript Biotech ( (HK:1548) ) has shared an announcement.
Legend Biotech Corporation, an associate of Genscript Biotech, announced new long-term clinical and translational data for its CARVYKTI® therapy from the CARTITUDE studies at the 2025 ASH Annual Meeting. This announcement highlights Legend’s ongoing advancements in treating relapsed/refractory multiple myeloma and introduces first-in-human data for a new dual-targeted CAR-T candidate, potentially strengthening its position in the cell therapy market.
The most recent analyst rating on (HK:1548) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation, incorporated in the Cayman Islands, operates in the biotechnology industry. It is associated with Legend Biotech Corporation, which focuses on developing innovative therapies, particularly in the field of cell therapy for cancer treatment.
YTD Price Performance: 53.05%
Average Trading Volume: 10,953,776
Technical Sentiment Signal: Hold
Current Market Cap: HK$32.75B
Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.